NYSE$BAX
Baxter International Inc · Q4 2023 earnings
Q4 2023 earnings · · Investor relations
Briefing
Reported a 4% increase in fourth-quarter sales and adjusted diluted EPS of $0.88.
Baxter International Inc. reported a 4% increase in worldwide sales from continuing operations, totaling $3.89 billion for the fourth quarter. U.S. GAAP diluted EPS from continuing operations was $0.14, and adjusted diluted EPS from continuing operations was $0.88. The company's performance exceeded previous guidance due to strong sales in Medical Products and Therapies, Kidney Care, and Pharmaceuticals segments.
- Fourth-quarter sales from continuing operations increased 4% on a reported basis and 3% on a constant currency basis.
- U.S. sales from continuing operations increased 2% on a reported basis.
- International sales from continuing operations increased 6% on a reported basis.
- Total net income attributable to Baxter on a U.S. GAAP basis was $245 million, or $0.48 per diluted share.
Headline financials
Revenue & EPS history
Baxter · Revenue · Quarterly
$3.89B
Revenue by segment
Baxter · $597M total across 2 segments · Q3 2023
- Pharmaceuticals$580M—97.2%
- Other$17M—2.8%
Forward guidance
Baxter expects full-year 2024 sales growth of approximately 2% on both a reported and constant currency basis, with adjusted earnings of $2.85 to $2.95 per diluted share. For the first quarter of 2024, the company anticipates sales growth of approximately 1% on a reported basis and adjusted earnings of $0.59 to $0.62 per diluted share.
Tailwinds
- Expects sales growth of approximately 2% on both a reported and constant currency basis for full-year 2024.
- Anticipates adjusted earnings of $2.85 to $2.95 per diluted share for full-year 2024.
- Projects sales growth of approximately 1% on a reported basis for first-quarter 2024.
- Estimates adjusted earnings of $0.59 to $0.62 per diluted share for first-quarter 2024.
- Focus on deleveraging and enhancing cash flow generation in 2024.
Headwinds
- The company is unable to predict with reasonable certainty the impact of legal proceedings.
- The company is unable to predict future business optimization actions.
- The company is unable to predict separation-related costs.
- The company is unable to predict integration-related costs.
- The company is unable to predict asset impairments and unusual gains and losses.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2023
-0.4%
Avg return
Earnings day
-2.0%
Avg return
5 days after
-0.9%
Avg return
30 days after
47%
34 / 72 earnings
Positive
+18.2%
Q4 2019
Best reaction
-16.0%
Q4 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +6.1% | -0.9% | +11.2% | |
| Q4 2025 | -16.0% | -6.9% | -21.9% | |
| Q3 2025 | -14.4% | -20.0% | -16.4% | |
| Q1 2025 | -1.6% | -4.0% | -2.1% | |
| Q4 2024 | +8.5% | +16.6% | +7.7% | |
| Q3 2024 | -5.0% | -9.5% | -11.8% | |
| Q2 2024 | +5.6% | +7.2% | +12.1% | |
| Q1 2024 | -8.6% | -10.5% | -15.5% | |
| Q4 2023 | +0.4% | +0.6% | +11.1% | |
| Q3 2023 | +3.6% | +4.3% | +11.5% | |
| Q2 2023 | -4.0% | -8.1% | -15.2% | |
| Q1 2023 | +3.5% | +2.0% | -10.4% | |
| Q4 2022 | -10.4% | -12.6% | -16.8% | |
| Q3 2022 | -4.6% | -6.7% | -2.8% | |
| Q2 2022 | -12.2% | -11.9% | -14.4% | |
| Q1 2022 | -0.0% | +1.4% | +7.2% | |
| Q4 2021 | -3.3% | -0.8% | -7.1% | |
| Q3 2021 | -3.6% | -2.0% | -6.9% | |
| Q2 2021 | -5.6% | -6.9% | -9.7% | |
| Q1 2021 | -1.5% | +0.5% | -5.6% | |
| Q4 2020 | +0.0% | -0.4% | +1.0% | |
| Q3 2020 | -0.7% | -1.1% | -2.8% | |
| Q2 2020 | -4.8% | -10.6% | -5.2% | |
| Q1 2020 | -4.0% | -3.0% | -1.6% | |
| Q4 2019 | +18.2% | +5.8% | +26.5% | |
| Q3 2019 | +18.2% | +5.8% | +26.5% | |
| Q2 2019 | +1.5% | +2.7% | +1.3% | |
| Q1 2019 | -0.1% | +0.0% | -1.5% | |
| Q4 2018 | +0.6% | +0.5% | +5.7% | |
| Q3 2018 | -8.1% | -9.0% | -0.2% | |
| Q2 2018 | -6.3% | -5.3% | -5.4% | |
| Q1 2018 | +5.5% | +5.5% | +9.0% | |
| Q4 2017 | -4.8% | -7.4% | -8.0% | |
| Q3 2017 | +0.9% | +0.3% | -0.4% | |
| Q2 2017 | -2.8% | -2.6% | -0.9% | |
| Q1 2017 | +4.2% | +4.5% | +10.2% | |
| Q4 2016 | +0.5% | +0.9% | +6.3% | |
| Q3 2016 | -2.1% | -2.6% | -3.9% | |
| Q2 2016 | +4.8% | +4.2% | +2.2% | |
| Q1 2016 | +1.3% | — | — | |
| Q4 2015 | +2.6% | — | — | |
| Q3 2015 | +3.7% | — | — | |
| Q2 2015 | +5.0% | — | — | |
| Q1 2015 | +1.1% | — | — | |
| Q4 2014 | +0.2% | — | — | |
| Q3 2014 | -1.6% | — | — | |
| Q2 2014 | -0.1% | — | — | |
| Q1 2014 | -0.4% | — | — | |
| Q4 2013 | -3.0% | — | — | |
| Q3 2013 | -2.3% | — | — | |
| Q2 2013 | +1.3% | — | — | |
| Q1 2013 | -1.6% | — | — | |
| Q4 2012 | +2.1% | — | — | |
| Q3 2012 | +0.0% | — | — | |
| Q2 2012 | +0.1% | — | — | |
| Q1 2012 | -0.4% | — | — | |
| Q4 2011 | +1.8% | — | — | |
| Q3 2011 | +2.8% | — | — | |
| Q2 2011 | -2.7% | — | — | |
| Q1 2011 | +1.7% | — | — | |
| Q4 2007 | -1.2% | — | — | |
| Q4 2010 | -1.2% | — | — | |
| Q3 2010 | +1.2% | — | — | |
| Q2 2010 | +0.3% | — | — | |
| Q1 2009 | +0.9% | — | — | |
| Q1 2010 | -0.8% | — | — | |
| Q4 2009 | -0.3% | — | — | |
| Q3 2008 | -0.8% | — | — | |
| Q3 2009 | -0.8% | — | — | |
| Q2 2008 | +2.2% | — | — | |
| Q2 2009 | +2.2% | — | — | |
| Q4 2008 | +2.2% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro